FDA Peptide Reclassification 2026: What Researchers Want Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # 503A Vs. 503B Compounding Pharmacies: Similarities & Differences The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York What Peptides Are Legal in the U.S.? Understanding FDA Approval, Compounding, and the Legal Gray Areas A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read